PYPD - PolyPid logo

PYPD

PolyPid

Rev โ€”top 1%5Y
Hold

PolyPid develops targeted, locally administered therapeutics using proprietary polymer-lipid encapsulation technology to improve surgical outcomes. Its lead product, D-PLEX100, aims to prevent surgical site infections during abdominal colorectal surgeries.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago โ†’$19today

Score Overview

1 Year
Scoreโ€”
Net Growth1.58%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth17.40%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth4.80%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

PolyPid fundamental performance

Across PolyPid's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 35M to -$ 34M. Revenue increased in 0% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 4.84โ€”
1 Year2025-08-12
$ 3.4241.52%
5 Years2021-08-12
$ 256.50-98.11%
All Time2020-06-26
$ 570.00-99.15%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 33M$ 11M
2025$ 0.00-$ 34M$ 12M
2024$ 0.00-$ 29M$ 15M
2023$ 0.00-$ 23M$ 5M
2022$ 0.00-$ 39M$ 12M
2021$ 0.00-$ 40M$ 32M
IPO2020$ 0.00-$ 35M$ 44M

Explore beyond PYPD

You're looking at PolyPid. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies